Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,550 | 641 | 3,856 |
| Samples | 429 | 97 | 327 |
| Peptides | 386 | 68 | 329 |
Function
RGS6 · Regulator of G protein signaling 6
This gene encodes a member of the RGS (regulator of G protein signaling) family of proteins, which are defined by the presence of a RGS domain that confers the GTPase-activating activity of these proteins toward certain G alpha subunits. This protein also belongs to a subfamily of RGS proteins characterized by the presence of DEP and GGL domains, the latter a G beta 5-interacting domain. The RGS proteins negatively regulate G protein signaling, and may modulate neuronal, cardiovascular, lymphocytic activities, and cancer risk. Many alternatively spliced transcript variants encoding different isoforms with long or short N-terminal domains, complete or incomplete GGL domains, and distinct C-terminal domains, have been described for this gene, however, the full-length nature of some of these variants is not known.[provided by RefSeq, Mar 2011].
Isoforms & Proteins
13 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000553525 | P49758-3 | 429 | 280 |
| ENST00000556437 | P49758-3 | 385 | 270 |
| ENST00000553530 | P49758 | 371 | 260 |
| ENST00000555571 | P49758 | 371 | 260 |
| ENST00000404301 | P49758-15 | 358 | 256 |
| ENST00000406236 | P49758-13 | 358 | 256 |
| ENST00000407322 | P49758-14 | 358 | 256 |
| ENST00000622468 | A0A087WTW9* | 351 | 248 |
| ENST00000355512 | P49758-16 | 344 | 246 |
| ENST00000402788 | A0A0A0MSB1* | 337 | 238 |
| ENST00000343854 | A0A0A0MRA9* | 332 | 231 |
| ENST00000434263 | A0ACM8QIH1* | 316 | 226 |
| ENST00000554782 | P49758-12 | 240 | 179 |
Gene Properties
Recurrent Mutations
All 280 amino-acid changes on canonical ENST00000553525 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RGS6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RGS6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Chordoma | 0/7 0% | 1/13 8% |
| Melanoma | 8/210 4% | 85/1899 4% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 21/304 7% | 22/1390 2% |
| Endometrial Carcinoma | 1/42 2% | 15/612 2% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 15/810 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 14/752 2% |
| Gastric Carcinoma | 0/74 0% | 28/1809 2% |
| Colorectal Carcinoma | 16/143 11% | 31/3239 1% |
| Bladder Carcinoma | 3/58 5% | 9/956 1% |
| Other Solid Cancers | 3/94 3% | 15/1515 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Head and Neck Carcinoma | 4/85 5% | 13/1574 1% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Ovarian Carcinoma | 2/109 2% | 5/998 0% |
| Hepatocellular Carcinoma | 2/46 4% | 12/2210 1% |
| Other Sarcomas | 0/69 0% | 4/699 1% |
| Glioma | 1/52 2% | 10/2127 0% |
| Prostate Carcinoma | 1/13 8% | 9/2105 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Non-Cancerous | 0/104 0% | 3/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 4/88 5% | 4/2534 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Esophageal Squamous Cell Carcinoma | 1/51 2% | 6/2550 0% |
| Breast Carcinoma | 2/144 1% | 7/3264 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
Mutation Distribution
Where RGS6 is mutated · all tissues, split by cell line vs tissue
How many mutations in RGS6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,550 mutations in RGS6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|